<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00015080</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-5-0012-5</org_study_id>
    <secondary_id>Y01-5-0012-5</secondary_id>
    <nct_id>NCT00015080</nct_id>
  </id_info>
  <brief_title>Naltrexone in Treatment of Cocaine Dependence - 5</brief_title>
  <official_title>Naltrexone in Treatment of Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cincinnati MDRU</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of naltrexone in the treatment of
      cocaine dependence as measured by: 1) decreased urine benzoylecgonine (BE) levels, 2)
      decreased cocaine use by self-report, 3) decreased cocaine craving, and 4) retention in
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind, placebo controlled study of the safety and efficacy of naltrexone in treating
      cocaine dependence in a patient sample that initiated the study while in an inpatient setting
      and were then followed-up for 3 months as outpatients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1995</start_date>
  <completion_date type="Actual">July 1996</completion_date>
  <primary_completion_date type="Actual">June 1996</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Retention</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Cocaine use</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Anxiety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Addiction severity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Global improvement</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Psychopathology</measure>
  </primary_outcome>
  <enrollment>0</enrollment>
  <condition>Cocaine-Related Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meet DSM-III-R criteria for cocaine dependency,

          2. 18 to 65 years of age,

          3. capable of understanding the study,

          4. voluntarily signed consent,

          5. male or non-pregnant female using approved form of birth control.

        Exclusion Criteria:

          1. abnormal liver function tests (SGOT, SGPT, or GGT greater than twice the normal
             values),

          2. opioid use within the last 7 days,

          3. use of neuroleptics,

          4. having a severe acute medical problem,

          5. unable to complete psychiatric rating scales, or

          6. judged by the investigator to be unlikely to comply with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene Somoza, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati MDRU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati MDRU</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Somoza, E., et al. A Double-Blind,Placebo Controlled Clinical Trial of Naltrexone as a Treatment for Cocaine Dependence. NIDA Research Monograph, 1998, 179, p. 295.. None</citation>
  </reference>
  <verification_date>December 1996</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2001</study_first_submitted>
  <study_first_submitted_qc>April 17, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2001</study_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <keyword>cocaine dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Cocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

